Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

If You Invested $1000 in Horizon Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More

by Zacks Equity Research

Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.

Sweta Killa headshot

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

by Sweta Killa

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Company News for Dec 13, 2022

by Zacks Equity Research

Companies in The News Are: COUP,HZNP,AMGN,RIVN,BA

Andrew Rocco headshot

The Return of "Merger Monday"

by Andrew Rocco

Two major deals in the biotech and software industry were inked this weekend.

Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion

by Zacks Equity Research

Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.

Wall Street Awaits Key Fed FOMC Decision

by Zacks Equity Research

Wall Street Awaits Key Fed FOMC Decision

Mark Vickery headshot

Busy Week Highlighted by Next Fed Rate Move

by Mark Vickery

Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years.

Reata Pharmaceuticals, Inc. (RETA) Down 1.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Horizon Therapeutics (HZNP) Up 38.3% Since Last Earnings Report?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants

by Zacks Equity Research

Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.

Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab

by Zacks Equity Research

Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.

Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.

Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 25% and 4.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Amryt Pharma PLC Sponsored ADR (AMYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon (HZNP) Completes Enrollment in Phase IV TED Study

by Zacks Equity Research

Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

by Zacks Equity Research

Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.

Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Horizon Therapeutics (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe

by Zacks Equity Research

Horizon's (HZNP) portfolio of marketed drugs, including Tepezza and Krystexxa, aid growth. The company is also working on the label expansion of its drugs. However, stiff competition remains a woe.

Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914

by Zacks Equity Research

Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the latter's ADX-914 for treating autoimmune diseases.